The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 29 of the 52 sources its claims cite were checked for support.
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Open accessPublished version of a preprint
Abstract
Recent progress in targeting KRAS G12C has provided both insight and inspiration for targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and anti-tumor efficacy of MRTX1133, a potent, selective and non-covalent KRAS G12D inhibitor. MRTX1133 demonstrated a high-affinity interaction with GDP-loaded KRAS G12D with K D and IC 50 values of ~0.2 pM and <2 nM, respectively, and ~700-fold selectivity for binding to KRAS G12D as compared to KRAS WT. MRTX1133 also demonstrated potent inhibition of activated KRAS G12D based on biochemical and co-crystal structural analyses. MRTX1133 inhibited ERK1/2 phosphorylation and cell viability in KRAS G12D-mutant cell lines, with median IC 50 values of ~5 nM, and demonstrated >1,000-fold selectivity compared to KRAS WT cell lines. MRTX1133 exhibited dose-dependent inhibition of KRAS-mediated signal transduction and marked tumor regression (≥30%) in a subset of KRAS G12D-mutant cell-line-derived and patient-derived xenograft models, including eight of 11 (73%) pancreatic ductal adenocarcinoma (PDAC) models. Pharmacological and CRISPR-based screens demonstrated that co-targeting KRAS G12D with putative feedback or bypass pathways, including EGFR or PI3Kα, led to enhanced anti-tumor activity. Together, these data indicate the feasibility of selectively targeting KRAS mutants with non-covalent, high-affinity small molecules and illustrate the therapeutic susceptibility and broad dependence of KRAS G12D mutation-positive tumors on mutant KRAS for tumor cell growth and survival.
Overview
CoChat Summary
TL;DR
MRTX1133 is a potent, selective, non-covalent KRASG12D inhibitor identified by structure-based drug design that binds both inactive and active KRASG12D and inhibits KRAS-dependent signaling. In preclinical models it produced marked tumor regression in KRASG12D-mutant xenografts, especially pancreatic ductal adenocarcinoma, and showed enhanced activity in rational combinations.
Key findings
- MRTX1133 bound GDP-bound KRASG12D with a SPR KD of ~0.2 pM versus 140 nM for KRAS WT (~700-fold selectivity); HTRF IC50 was <2 nM for inactive KRASG12D and 9 nM for active KRASG12D effector interaction.
- In KRASG12D-mutant cell lines, MRTX1133 inhibited pERK in 24/25 lines with IC50 values of 0.6–13.7 nM (median 6.1 nM), versus median >3,000 nM in nonKRASG12D lines; viability IC50 medians were 5.3 nM in 3D and 26 nM in 2D assays.
- In vivo, MRTX1133 at 30 mg/kg BID caused 85% regression in HPAC xenografts, 16% regression at 10 mg/kg BID, and 81% tumor growth inhibition at 3 mg/kg BID; in Panc 04.03, 10 and 30 mg/kg BID produced 60% and 74% regression, respectively.
- Across 25 KRASG12D-mutant models, 11/25 had ≥30% tumor regression, including 8/11 (73%) PDAC and 2/8 (25%) CRC models; no significant efficacy was seen in four nonKRASG12D-mutant models. Cetuximab plus MRTX1133 improved anti-tumor efficacy in all 7 models tested, and BYL-719 combinations increased activity in CRC and pancreatic models.
Methods
- Structure-based drug design, SPR binding assays, HTRF competition/effector interaction assays, X-ray crystallography, and cellular signaling/viability assays across 25 KRASG12D-mutant and 7 nonKRASG12D-mutant cancer cell lines.
- In vivo studies used immunocompromised mice bearing subcutaneous or orthotopic cell line-derived xenografts and patient-derived xenografts; MRTX1133 was administered intraperitoneally at 3, 10, or 30 mg/kg BID, with tumor volume, immunohistochemistry, active RAS ELISA, RNAseq, CRISPR/Cas9 screens, and combination screens.
- Statistical comparisons used ANOVA or two-tailed Student’s t-test with p<0.05 considered significant; group sizes were typically n=3–6 mice per group.
Limitations
- The paper states that the level of oncogene addiction to KRASG12D in cancers harboring this mutation is not fully understood; that lower PTEN and CDKN2A RNA expression trends did not reach statistical significance; and that KEAP1 findings were from a preliminary analysis. It also notes that consequences of targeting KRAS WT in adult mammals are unknown.
- Evident from the text: all efficacy and safety data are preclinical (cell lines and mouse xenograft/orthotopic models), with no human clinical outcomes; MRTX1133 was given intraperitoneally in mice, not by a clinically validated route; and feedback reactivation of ERK/S6 was observed, which may limit response durability.
- The provided text is a preprint that explicitly states it has not undergone peer review and should not be considered conclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
13 Valid · 5 Not valid · 12 Not checked · 106 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of note, in a preliminary analysis, the response rate of MRTX849 in NSCLC patients harboring mutations in both KRAS G12C and KEAP1 was reduced compared to the response rate in KRAS G12C , KEAP1 WT patients [13, 14].”
What the sources say
- Not matchedcites [13] Janne, P. et al. KRYSTAL-1: updated safety and efficacy data with adagrasib (MRTX849) in NSCLC with KRASG12C mutation from a phase 1/2 study. https://www.mirati.com/wp-content/uploads/Janne-849-001_NSCLC-ENA-Presentation_25Oct2020_FINAL.pdf (2020).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [14] Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021). sourceExperimental — accuracy not yet measured
The Discussion (page not provided) reports a lower response percentage in KEAP1-mutated than KEAP1-wild-type tumors, but this exploratory finding concerns sotorasib, not MRTX849. The paper therefore does not support the claim about response to MRTX849. (LLM, conf=0.88)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given the particular relevance of the EGFR pathway in the pathogenesis of pancreatic and colorectal cancers [16, 17]”
What the sources say
- Partly supportedcites [16] Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004). sourceExperimental — accuracy not yet measured
The paper’s discussion of EGFR states that it is relevant to colorectal cancer and describes cancer-related processes regulated by its signaling pathway (results section; page unavailable). The copy does not make the same claim about pancreatic cancer; pancreatic cancer appears only in a cited reference title. (LLM, conf=0.88)
- Partly supportedcites [17] Navas, C. et al. EGF receptor signaling is essential for K-Ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22, 318–330 (2012). sourceExperimental — accuracy not yet measured
The Discussion states that initiation of K-Ras-driven pancreatic lesions and cancer depends on EGFR signaling. But the Results report that K-Ras-driven intestinal tumors developed without EGFR signaling, so this paper does not support the same broad claim about colorectal cancer pathogenesis. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Studies conducted with MRTX849 in KRAS G12C mutated nonclinical tumor cell lines and in vivo models generally demonstrated a lack of effectiveness for the combination with BYL719 [4].”
What the sources say
- Could not verifycites [4] Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020). sourceExperimental — accuracy not yet measured
The Results section on the combination screen reports testing inhibitors of several pathways, including PI3K, with MRTX849, but does not identify BYL719 or report its effectiveness. Searches for BYL719, alpelisib, and PI3K-combination outcomes found no passage establishing the claimed lack of effectiveness in cell lines or in vivo models. (LLM, conf=0.72)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prior studies with KRAS G12C , RAF, and MEK inhibitors indicated that blockade of KRAS-dependent signaling activated a transcriptional program suppressing DUSP , SPRY , and ETV family genes which cooperate to mediate increased signaling flux though RTK, SOS, and MEK/ERK family members resulting in conditional bypass dependence on KRAS [4, 32-34].”
What the sources say
- Partly supportedcites [4] Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Could not verifycites [32] Rozengurt, E., Sinnett-Smith, J. & Kisfalvi, K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 16, 2505–2511 (2010). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Could not verifycites [33] Ulanet, D. B., Ludwig, D. L., Kahn, C. R. & Hanahan, D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc. Natl Acad. Sci. USA 107, 10791–10798 (2010). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [34] Cespedes, M. V. et al. K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis 27, 2190–2200 (2006). source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, studies evaluating the anti-tumor activity of KRAS G12C inhibitors indicated that the dependence of cells on KRAS mutations for growth and survival as oncogenic drivers was distinct in in vitro cell lines compared with in vivo model systems ([4, 22]).”
What the sources say
- Partly supportedcites [4] Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54–71 (2020). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [22] Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578–589 (2018). source
The Results compare KRAS G12C dependency in in vitro cultures and in vivo xenograft models. The Discussion states that adherent monolayer cultures significantly underestimate KRAS dependence in vivo, while 3D cultures better predict in vivo sensitivity. Page numbers were not supplied. (LLM, conf=0.93)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
74 more claims · 2 with their cited sources checked
Create a free account to see all 136 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 50
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intrinsic hydrolysis rate of G12C is inherently high; hence, the fact that the loss of the GAP NF1 can act as a resistance mechanism for KRAS inhibition suggests that NF1 may have KRAS-independent functions [4,56,111].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MRTX1133 (30 mg/kg) was administered via intraperitoneal injection, twice per day, at the maximum in vivo tolerated dose as described by the manufacturer (30, 31), causing no significant cytotoxic side effects during treatment.”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MRTX1133, a non-covalent inhibitor that occupies the switch-II pocket, has shown anti-tumor efficacy by hindering nucleotide exchange and effector binding. 4,5”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additional investigations of combination therapy strategies with MRTX1133 in preclinical models of PDAC have suggested that co-targeting of EGFR may have enhanced efficacy over monotherapy (30, 34).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Recent preclinical work with MRTX1133 has demonstrated excellent responses in cell line and xenograft models of PDAC (30, 32).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [30]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ MRTX1133 Combined with BYL-719 Provides Improved Anti-tumor Response in Pancreatic and Colon Tumor Models
“Tumor volumes at Day 15 for the MRTX1133 BID daily for 2 days + cetuximab combination treatment group was determined to be statistically significant vs MRTX1133 BID daily for 2 days or BYL-719 single agent treatment groups”
§ MRTX1133 Combined with BYL-719 Provides Improved Anti-tumor Response in Pancreatic and Colon Tumor Models
“BYL-719 at 15 mg/kg daily, or the combination with the twice weekly schedule of MRTX1133 was administered intraperitoneally to mice bearing the LS180 cell line xenograft”
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Towards automated crystallographic structure refinement with phenix.refine
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Cited by
Large language models in medicine
Thirunavukarasu, A. J., Ting, D. S. J., Elangovan, K., Gutierrez, L., Tan, T. F., & Ting, D. S. W. (2023) · Nature Medicine · doi:10.1038/s41591-023-02448-8 · Cited by 3,944
“However, frequent errors in medical notes, scientific literature and other internet material will continue to hamper LLM performance; clinical practice, scientific inquiry and dissemination of knowledge are not, and will never be, executed perfectly 99,100 .”
BackgroundPancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
“MRTX1133 induced tumour regression, reduced tumour-infiltrating myeloid-derived suppressor cells (MDSCs), increased M1-like macrophages and expanded the number of tumour-infiltrating cytotoxic T cells in preclinical Kras G12D mouse tumour models 105,106 .”
Metadata
- Authors
- Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., Trinh, D., Hoffman, N., Wang, X., David Lawson, J., Gunn, R. J., Smith, C. R., Thomas, N. C., Martinson, M., Bergstrom, A., Sullivan, F., Bouhana, K., Winski, S., He, L., Fernandez-Banet, J., Pavlicek, A., Haling, J. R., Rahbaek, L., Marx, M. A., Olson, P., & Christensen, J. G.
- Affiliations
- Mirati Therapeutics (United States) (US)
- Array BioPharma (United States) (US)
- Corresponding author
- Christensen, James G.
- ORCID
- Hallin, Jill
- Bowcut, Vickie
- Calinisan, Andrew
- Briere, David M.
- Hargis, Lauren
- Engstrom, Lars D.
- Laguer, Jade
- Vanderpool, Darin
- Lifset, Ella
- Wang, Xiaolun
- David Lawson, J.
- Gunn, Robin J.
- Smith, Christopher R.
- Thomas, Nicole C.
- Sullivan, Francis
- Winski, Shannon
- Fernandez-Banet, Julio
- Haling, Jacob R.
- Marx, Matthew A.
- Olson, Peter
- Christensen, James G.
- Venue
- Nature Medicine
- Published
- 2022-10
- Volume
- 28
- Issue
- 10
- Pages
- 2171-2182
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4304084008
- Semantic Scholar
- b7c117afde78d9d5211e96d5c562a1fdf63b10d7
- Cited by
- 553
- References
- 49
- Citations by year
- 2026: 159 · 2025: 159 · 2024: 138 · 2023: 90 · 2022: 7
- FWCI
- 28.97
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- Research Square (submittedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy (DE‐ AC02‐06CH11357, Contract No. DE-AC02-06CH11357., AC02‐06CH11357, S10OD021527, P30 GM124165, 06CH11357, No. DE-AC02-06CH11357, DE-AC02-)
- National Institutes of Health (S10OD021527, DE-AC02–06CH11357)
- Office of Science (P30 GM124165, Contract No. DE-AC02-06CH11357, AC02‐06CH11357, DE-AC02, No. DE-AC02-06CH11357., 06CH11357, DE-AC02-06CH11357)
- National Institute of General Medical Sciences (DE-AC02-06CH11357, P30GM124165)
- Office of Research Infrastructure Programs, National Institutes of Health (S10OD021527)
- Argonne National Laboratory (DE- AC02-06-CH11357, DE-AC02, AC02–06CH11357, No. DE-AC02-06CH11357, 06CH11357, Contract No. DE-AC02-06CH11357., P30 GM124165)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12D, MRTX1133, structure-based drug design, ERK1/2 phosphorylation, EGFR, PI3Kα, pancreatic ductal adenocarcinoma, patient-derived xenografts, antitumor efficacy, co-targeting
- MeSH terms
- Humans, Mutation, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Cell Line, Tumor, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. https://app.cochat.ai/papers/10.1038/s41591-022-02007-7
- The paper
- Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., Trinh, D., Hoffman, N., Wang, X., David Lawson, J., Gunn, R. J., Smith, C. R., Thomas, N. C., Martinson, M., Bergstrom, A., . . . Christensen, J. G. (2022). Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine. https://doi.org/10.1038/s41591-022-02007-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.





